In summary, our research demonstrated that the downregulation of lncRNA SBF2-AS1 could inhibit tumorigenesis and progression of BC by sponging miR-143 and repressing RRS1, which may provide novel targets for the management of BC. The gene discussed is SBF2; the disease is breast cancer.